Clinical characteristics of iTTP patients at baseline, within 30 days of remission (month 0) and 6 months after remission (month 6)
| . | Baseline . | Month 0 . | Month 6 . |
|---|---|---|---|
| Demographic characteristics (N = 7)* | |||
| Women, n (%) | 5 (71%) | ||
| Age at symptom onset, y | |||
| Mean (SD) | 48 (19) | ||
| Median (25th, 75th percentiles) | 50 (30, 59) | ||
| Range | 21-77 | ||
| Body mass index, kg/m2 | |||
| Mean (SD) | 36 (8) | ||
| Median (25th, 75th percentiles) | 33 (33, 41) | ||
| Range | 25-48 | ||
| Clinical characteristics | |||
| Platelet count*, × 109/L† | |||
| Mean (SD) | 22 (25) | 251 (41) | 239 (44) |
| Median (25th, 75th percentiles) | 11 (10, 26) | 248 (229, 290) | 239 (223, 261) |
| Range | <10-76 | 183-299 | 161-306 |
| Hemoglobin, g/L | |||
| Mean (SD) | 84 (18) | 126 (13) | 128 (17) |
| Median (25th, 75th percentiles) | 79 (78, 102) | 126 (122, 141) | 121 (116, 149) |
| Range | 53-106 | 102, 142 | 109 – 153 |
| Lactate dehydrogenase, U/L (upper limit of normal, 214 U/L) | |||
| Mean (SD) | 1465 (813) | 254 (114) | 217 (83) |
| Median (25th, 75th percentiles) | 1420 (671, 2256) | 249 (161, 339) | 197 (143, 263) |
| Range | 417-2500 | 79, 413 | 134-371 |
| ADAMTS13,† % | |||
| Mean (SD) | <1‡ | 61 (41)§ | 75 (40)§ |
| Median (25th, 75th percentiles) | <1 | 81 (19, 91) | 89 (52, 114) |
| Range | <1 | <1, 96 | <1->114 |
| Serum creatinine, µmol/L | |||
| Mean (SD) | 123 (40) | 100 (56) | 75 (18) |
| Median (25th, 75th percentiles) | 122 (95, 157) | 73 (66, 107) | 71 (64, 76) |
| Range | 65-186 | 58, 220 | 62-115 |
| Missing, n (%) | 0 (0%) | 0 (0%) | |
| Immunosuppressive therapy | |||
| Prednisone, n (%) | 7 (100%) | ||
| Rituximab, n (%) | 6 (86%) | ||
| Vincristineǁ | 2 (29%) |
| . | Baseline . | Month 0 . | Month 6 . |
|---|---|---|---|
| Demographic characteristics (N = 7)* | |||
| Women, n (%) | 5 (71%) | ||
| Age at symptom onset, y | |||
| Mean (SD) | 48 (19) | ||
| Median (25th, 75th percentiles) | 50 (30, 59) | ||
| Range | 21-77 | ||
| Body mass index, kg/m2 | |||
| Mean (SD) | 36 (8) | ||
| Median (25th, 75th percentiles) | 33 (33, 41) | ||
| Range | 25-48 | ||
| Clinical characteristics | |||
| Platelet count*, × 109/L† | |||
| Mean (SD) | 22 (25) | 251 (41) | 239 (44) |
| Median (25th, 75th percentiles) | 11 (10, 26) | 248 (229, 290) | 239 (223, 261) |
| Range | <10-76 | 183-299 | 161-306 |
| Hemoglobin, g/L | |||
| Mean (SD) | 84 (18) | 126 (13) | 128 (17) |
| Median (25th, 75th percentiles) | 79 (78, 102) | 126 (122, 141) | 121 (116, 149) |
| Range | 53-106 | 102, 142 | 109 – 153 |
| Lactate dehydrogenase, U/L (upper limit of normal, 214 U/L) | |||
| Mean (SD) | 1465 (813) | 254 (114) | 217 (83) |
| Median (25th, 75th percentiles) | 1420 (671, 2256) | 249 (161, 339) | 197 (143, 263) |
| Range | 417-2500 | 79, 413 | 134-371 |
| ADAMTS13,† % | |||
| Mean (SD) | <1‡ | 61 (41)§ | 75 (40)§ |
| Median (25th, 75th percentiles) | <1 | 81 (19, 91) | 89 (52, 114) |
| Range | <1 | <1, 96 | <1->114 |
| Serum creatinine, µmol/L | |||
| Mean (SD) | 123 (40) | 100 (56) | 75 (18) |
| Median (25th, 75th percentiles) | 122 (95, 157) | 73 (66, 107) | 71 (64, 76) |
| Range | 65-186 | 58, 220 | 62-115 |
| Missing, n (%) | 0 (0%) | 0 (0%) | |
| Immunosuppressive therapy | |||
| Prednisone, n (%) | 7 (100%) | ||
| Rituximab, n (%) | 6 (86%) | ||
| Vincristineǁ | 2 (29%) |
There are no missing values for these demographic and clinical characteristics.
Platelet count < 10 × 109/L (our laboratory does not quantify < 10 × 109/L); a value of 5 × 109/L was given for this summary.
All patients had ADAMTS13 levels < 10% and inhibitor levels > 14 U/mL. All patients had detectable inhibitor level.
A value of <1% was replaced with a value of 1 for this summary; a value of >114 was replaced with 114 for this summary. Inhibitors were not run because most patients had normalized their ADAMTS13 activity.
Used in cases of refractory iTTP not responsive to TPE and corticosteroids alone.